A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Conditions: Carcinoma, Neuroendocrine; Tumor, Neuroendocrine; Tumors, Neuroendocrine; Neuroendocrine; Carcinoma; Small Cell; Receptors

Interventions: Drug: Belinostat; Drug: Cisplatin; Drug: Etoposide

Sponsors: National Cancer Institute (NCI)

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 10, 2024Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments